<?xml version="1.0"?><root>
	<abstract>
		<sent>
			<text>PMID:12345</text>
			
		</sent>
	</abstract>

	<abstract>
		<sent>
			<text>PMID:10228190</text>
			
		</sent>
		<sent>
			<text>We conducted a randomized , multicenter , double - blind , placebo-controlled trial of infliximab for the treatment of fistulas in patients with Crohn 's disease .</text>
			<entity class='Intervention' UMLS='C0666743:infliximab' index='T1' start='14'> infliximab </entity>
			 <entity class='Participant' UMLS='' index='T2' start='19'> fistulas </entity>
			 <entity class='Participant' UMLS='C0012634:disease,C0010346:Crohn' index='T3' start='23'> Crohn 's disease </entity>
		</sent>
		<sent>
			<text>METHODS : The study included 94 adult patients who had draining abdominal or perianal fistulas of at least three months ' duration as a complication of Crohn 's disease .</text>
			<entity class='Participant' UMLS='C0000726:abdominal,C0442158:perianal' index='T4' start='10'> draining abdominal or perianal fistulas of at least three months ' duration </entity>
			 <entity class='Participant' UMLS='C0012634:disease,C0010346:Crohn' index='T5' start='26'> Crohn 's disease </entity>
		</sent>
		<sent>
			<text>Patients were randomly assigned to receive one of three treatments : placebo ( 31 patients ) , 5 mg of infliximab per kilogram of body weight ( 31 patients ) , or 10 mg of infliximab per kilogram ( 32 patients ) ; all three were to be administered intravenously at weeks 0 , 2 , and 6 .</text>
			<entity class='Intervention' UMLS='C0032042:placebo' index='T6' start='11'> placebo </entity>
			 <attribute class='measure' index='T7' start='17'> 5 mg </attribute>
			 <entity class='Intervention' UMLS='C1305866:body weight,C0666743:infliximab' index='T8' start='20'> infliximab per kilogram of body weight </entity>
			 <attribute class='measure' index='T9' start='32'> 10 mg </attribute>
			 <entity class='Intervention' UMLS='C0666743:infliximab' index='T10' start='35'> infliximab per kilogram </entity>
		</sent>
		<sent>
			<text>The primary end point was a reduction of 50 percent or more from base line in the number of draining fistulas observed at two or more consecutive study visits .</text>
			<attribute class='modifier' index='T11' start='6'> reduction </attribute>
			 <attribute class='measure' index='T12' start='8'> 50 percent </attribute>
			 <entity class='Outcome' UMLS='' index='T13' start='17'> number of draining fistulas </entity>
		</sent>
		<sent>
			<text>A secondary end point was the closure of all fistulas .</text>
			<entity class='Outcome' UMLS='C0441508:Closure of fistula' index='T14' start='6'> closure of all fistulas </entity>
		</sent>
	</abstract>

	<abstract>
		<sent>
			<text>PMID:10392863</text>
			
		</sent>
		<sent>
			<text>Directional atherectomy ( n = 496 ) or balloon angioplasty ( n = 490 ) was performed in 986 patients ; late QA follow - up was available in 767 patients ( 77.7 % ) .</text>
			<entity class='Intervention' UMLS='C0441488:Directional atherectomy' index='T15' start='0'> Directional atherectomy </entity>
			 <entity class='Intervention' UMLS='C0002996:balloon angioplasty' index='T16' start='8'> balloon angioplasty </entity>
		</sent>
		<sent>
			<text>QA analysis was performed by 2 independent observers using the CMS and ARTREK systems .</text>
			<entity class='Outcome' UMLS='' index='T17' start='0'> QA analysis </entity>
			 <entity class='Intervention' UMLS='' index='T18' start='10'> CMS </entity>
		</sent>
	</abstract>

	<abstract>
		<sent>
			<text>PMID:10400005</text>
			
		</sent>
		<sent>
			<text>METHODS : This randomized , double - blind , placebo - controlled multicenter trial enrolled subjects with symptomatic HF and systolic dysfunction ( left ventricular ejection fraction smaller_than or =35 % ) .</text>
			<entity class='Intervention' UMLS='C0032042:placebo' index='T19' start='9'> placebo </entity>
			 <entity class='Participant' UMLS='C0231221:Asymptomatic' index='T20' start='17'> symptomatic HF </entity>
			 <entity class='Participant' UMLS='C0749225:systolic dysfunction' index='T21' start='20'> systolic dysfunction </entity>
			 <entity class='Participant' UMLS='C0042508:ventricular ejection fraction' index='T22' start='23'> left ventricular ejection fraction </entity>
		</sent>
		<sent>
			<text>Central hemodynamics were assessed at baseline , during a 24 - h IV infusion and for 4 h postinfusion .</text>
			<entity class='Outcome' UMLS='C4281788:hemodynamics,C0719205:Central' index='T23' start='0'> Central hemodynamics </entity>
		</sent>
	</abstract>

	<abstract>
		<sent>
			<text>PMID:10403850</text>
			
		</sent>
		<sent>
			<text>METHODS : We studied 21 patients with acute colonic pseudo-obstruction .</text>
			<entity class='Participant' UMLS='C0009377:colonic pseudo-obstruction' index='T24' start='7'> acute colonic pseudo-obstruction </entity>
		</sent>
		<sent>
			<text>All had abdominal distention and radiographic evidence of colonic dilation , with a cecal diameter of at least 10 cm , and had had no response to at least 24 hours of conservative treatment .</text>
			<entity class='Outcome' UMLS='C0000731:abdominal distention' index='T25' start='2'> abdominal distention </entity>
			 <entity class='Outcome' UMLS='C0009368:colonic' index='T26' start='8'> colonic dilation </entity>
			 <entity class='Outcome' UMLS='C0007531:cecal' index='T27' start='13'> cecal diameter </entity>
		</sent>
		<sent>
			<text>We randomly assigned 11 to receive 2.0 mg of neostigmine intravenously and 10 to receive intravenous saline .</text>
			<attribute class='measure' index='T28' start='6'> 2.0 mg </attribute>
			 <entity class='Intervention' UMLS='C0027679:neostigmine' index='T29' start='9'> neostigmine </entity>
			 <entity class='Intervention' UMLS='C0723199:salinex' index='T30' start='15'> intravenous saline </entity>
		</sent>
		<sent>
			<text>A physician who was unaware of the patients ' treatment assignments recorded clinical response ( defined as prompt evacuation of flatus or stool and a reduction in abdominal distention ) , abdominal circumference , and measurements of the colon on radiographs .</text>
			<entity class='Outcome' UMLS='C1704632:response' index='T31' start='12'> clinical response </entity>
			 <entity class='Outcome' UMLS='C1282573:evacuation,C0016204:flatus,C0015733:stool' index='T32' start='18'> evacuation of flatus or stool </entity>
			 <attribute class='modifier' index='T33' start='25'> reduction </attribute>
			 <entity class='Outcome' UMLS='C0000731:abdominal distention' index='T34' start='27'> abdominal distention ) </entity>
			 <entity class='Outcome' UMLS='C1300813:abdominal circumference' index='T35' start='31'> abdominal circumference </entity>
			 <entity class='Outcome' UMLS='C1306645:radiographs,C0009368:colon' index='T36' start='38'> colon on radiographs </entity>
		</sent>
		<sent>
			<text>Patients who had no response to the initial injection were eligible to receive open - label neostigmine three hours later .</text>
			<entity class='Intervention' UMLS='C0027679:neostigmine,C0181496:label' index='T37' start='15'> label neostigmine </entity>
		</sent>
	</abstract>

	<abstract>
		<sent>
			<text>PMID:10438706</text>
			
		</sent>
		<sent>
			<text>Four hundred thirteen patients smaller_than/=75 years of age and with newly diagnosed APL were included .</text>
			<entity class='Participant' UMLS='' index='T38' start='7'> age </entity>
			 <entity class='Participant' UMLS='C0011900:diagnosed' index='T39' start='11'> diagnosed APL </entity>
		</sent>
		<sent>
			<text>Induction treatment was stratified on white blood cell ( WBC ) count and age : patients smaller_than/=65 years of age and with an initialWBCcount of smaller_than/=5,000 / microL ( n = 208 ) were randomized between ATRA --larger_than CT and ATRA+CT ( initially randomized patients ) ; patients with aWBCcount greater than ( highWBCcount group , n = 163 ) and patients 66 to 75 years of age with aWBCcount greater than 5,000 / microL ( elderly group , n = 42 ) were not initially randomized and received ATRA + CT from day 1 and ATRA --larger_than CT , respectively .</text>
			<entity class='Outcome' UMLS='C0005767:blood' index='T40' start='5'> white blood cell ( WBC ) count </entity>
			 <entity class='Outcome' UMLS='' index='T41' start='13'> age </entity>
			 <entity class='Participant' UMLS='' index='T42' start='19'> age </entity>
			 <entity class='Intervention' UMLS='' index='T43' start='25'> smaller_than/=5,000 / microL </entity>
			 <entity class='Intervention' UMLS='' index='T44' start='36'> ATRA --larger_than CT </entity>
			 <entity class='Intervention' UMLS='' index='T45' start='40'> ATRA+CT </entity>
			 <entity class='Participant' UMLS='' index='T46' start='49'> aWBCcount greater </entity>
			 <attribute class='measure' index='T47' start='62'> 66 to 75 years </attribute>
			 <entity class='Participant' UMLS='' index='T48' start='67'> age </entity>
			 <attribute class='measure' index='T49' start='72'> 5,000 / microL </attribute>
			 <entity class='Participant' UMLS='' index='T50' start='76'> elderly </entity>
			 <entity class='Intervention' UMLS='' index='T51' start='89'> ATRA + CT </entity>
			 <entity class='Intervention' UMLS='' index='T52' start='96'> ATRA --larger_than CT </entity>
		</sent>
		<sent>
			<text>All patients achieving CR received 2 additional DNR-AraC courses ( only 1 in patients 66 to 75 years of age ) and were then randomized for maintenance between no treatment , intermittent ATRA ( 15 days every 3 months ) for 2 years , continuous low - dose CT ( 6 mercaptopurine + methotrexate ) for 2 years , or both , using a 2 - by - 2 factorial design .</text>
			<entity class='Participant' UMLS='' index='T53' start='3'> CR </entity>
			 <entity class='Intervention' UMLS='' index='T54' start='32'> ATRA </entity>
		</sent>
	</abstract>

	<abstract>
		<sent>
			<text>PMID:10459902</text>
			
		</sent>
		<sent>
			<text>METHODS : Eight patients with cystic fibrosis were randomly assigned DNA - lipid complex ( active ) by nebulisation into the lungs followed 1 week later by administration to the nose .</text>
			<entity class='Participant' UMLS='C0010674:cystic fibrosis' index='T55' start='5'> cystic fibrosis </entity>
			 <entity class='Intervention' UMLS='C1659427:nebulisation' index='T56' start='18'> nebulisation </entity>
		</sent>
		<sent>
			<text>Eight control patients followed the same protocol but with the lipid alone ( placebo ) .</text>
			<entity class='Intervention' UMLS='C0032042:placebo,C0439044:alone' index='T57' start='10'> lipid alone ( placebo ) </entity>
		</sent>
		<sent>
			<text>Safety was assessed clinically , by radiography , by pulmonary function , by induced sputum , and by histological analysis .</text>
			<entity class='Outcome' UMLS='' index='T58' start='0'> Safety </entity>
			 <entity class='Outcome' UMLS='C0024109:pulmonary,C0031843:function' index='T59' start='9'> pulmonary function </entity>
			 <entity class='Outcome' UMLS='C0038056:sputum' index='T60' start='14'> sputum </entity>
		</sent>
		<sent>
			<text>Efficacy was assessed by analysis of vector-specific CFTR DNA and mRNA , in - vivo potential difference , epifluorescence assay of chloride efflux , and bacterial adherence .</text>
			<entity class='Outcome' UMLS='' index='T61' start='0'> Efficacy </entity>
			 <entity class='Outcome' UMLS='C1552740:specific' index='T62' start='6'> vector-specific CFTR DNA and mRNA </entity>
			 <entity class='Outcome' UMLS='' index='T63' start='21'> chloride efflux </entity>
			 <entity class='Outcome' UMLS='' index='T64' start='25'> bacterial adherence </entity>
		</sent>
		<sent>
			<text>FINDINGS : Seven of the eight patients receiving theactivecomplex reported mild influenza - like symptoms that resolved within 36 h .</text>
			<entity class='Participant' UMLS='' index='T65' start='8'> theactivecomplex </entity>
			 <entity class='Outcome' UMLS='C0021400:influenza,C1457887:symptoms,C0870814:like' index='T66' start='10'> mild influenza - like symptoms </entity>
		</sent>
		<sent>
			<text>Six of eight patients in both theactiveandplacebogroups reported mild airway symptoms over a period of 12 h following pulmonary administration .</text>
			<entity class='Intervention' UMLS='' index='T67' start='6'> theactiveandplacebogroups </entity>
			 <entity class='Outcome' UMLS='C1457887:symptoms,C0178987:airway' index='T68' start='8'> mild airway symptoms </entity>
			 <entity class='Participant' UMLS='C1533734:administration,C0024109:pulmonary' index='T69' start='18'> pulmonary administration </entity>
		</sent>
		<sent>
			<text>No specific treatment was required for either event .</text>
			
		</sent>
		<sent>
			<text>Pulmonary administration resulted in a significant ( p smaller_than 0.05 ) degree of correction of the chloride abnormality in the patients receivingactivetreatment but not in those onplacebowhen assessed by in - vivo potential difference and chloride efflux .</text>
			<entity class='Intervention' UMLS='C1533734:administration,C2707265:Pulmonary' index='T70' start='0'> Pulmonary administration </entity>
			 <entity class='Outcome' UMLS='C0542560:degree,C1704258:Abnormality' index='T71' start='11'> degree of correction of the chloride abnormality </entity>
			 <entity class='Intervention' UMLS='' index='T72' start='26'> onplacebowhen </entity>
			 <entity class='Outcome' UMLS='' index='T73' start='35'> chloride efflux </entity>
		</sent>
		<sent>
			<text>Bacterial adherence was also reduced .</text>
			<entity class='Outcome' UMLS='C0004618:Bacteria' index='T74' start='0'> Bacterial adherence </entity>
			 <attribute class='modifier' index='T75' start='4'> reduced </attribute>
		</sent>
		<sent>
			<text>We detected no alterations in the sodium transport abnormality .</text>
			<attribute class='modifier' index='T76' start='3'> alterations </attribute>
			 <entity class='Outcome' UMLS='C3495449:transport,C1704258:Abnormality' index='T77' start='6'> sodium transport abnormality </entity>
		</sent>
		<sent>
			<text>A similar pattern occurred following nasal administration .</text>
			<entity class='Intervention' UMLS='C0001560:nasal administration' index='T78' start='5'> nasal administration </entity>
		</sent>
	</abstract>

	<abstract>
		<sent>
			<text>PMID:10475304</text>
			
		</sent>
		<sent>
			<text>Thirty patients were included in a prospective , open study and were randomized into two groups .</text>
			
		</sent>
		<sent>
			<text>In Group I , the patients were tracheally extubated as soon as possible after surgery .</text>
			<entity class='Outcome' UMLS='' index='T79' start='7'> tracheally extubated </entity>
			 <entity class='Intervention' UMLS='C0543467:surgery' index='T80' start='14'> surgery </entity>
		</sent>
		<sent>
			<text>In Group II , the patients were sedated with propofol for 2 h after surgery .</text>
			<entity class='Outcome' UMLS='C0235195:sedated' index='T81' start='7'> sedated </entity>
			 <entity class='Intervention' UMLS='C0033487:propofol' index='T82' start='9'> propofol </entity>
			 <entity class='Participant' UMLS='C0543467:surgery' index='T83' start='14'> surgery </entity>
		</sent>
		<sent>
			<text>V ( O2 ) , catecholamine concentration , mean arterial pressure ( MAP ) , and heart rate ( HR ) were measured during anesthesia , at extubation , and 30 min after extubation .</text>
			<entity class='Outcome' UMLS='' index='T84' start='0'> V ( O2 ) </entity>
			 <entity class='Outcome' UMLS='C0007412:catecholamine,C0086045:concentration' index='T85' start='5'> catecholamine concentration </entity>
			 <entity class='Outcome' UMLS='C0428886:mean arterial pressure' index='T86' start='8'> mean arterial pressure ( MAP ) </entity>
			 <entity class='Outcome' UMLS='C0018810:heart rate' index='T87' start='16'> heart rate ( HR ) </entity>
			 <entity class='Participant' UMLS='C0002903:anesthesia' index='T88' start='24'> anesthesia </entity>
			 <entity class='Outcome' UMLS='C0553891:extubation' index='T89' start='27'> extubation </entity>
			 <entity class='Participant' UMLS='C0553891:extubation' index='T90' start='33'> extubation </entity>
		</sent>
	</abstract>

	<abstract>
		<sent>
			<text>PMID:10515020</text>
			
		</sent>
		<sent>
			<text>STUDY DESIGN : A prospective double - blind randomized trial in 31 patients .</text>
			
		</sent>
		<sent>
			<text>METHODS : Thirty - one patients with a history of at least 1 year of chronic low back pain were selected on the basis of a positive response to a diagnostic nerve blockade and subsequently randomly assigned to one of two treatment groups .</text>
			<entity class='Participant' UMLS='C0457949:chronic low back pain' index='T91' start='15'> chronic low back pain </entity>
			 <entity class='Outcome' UMLS='C0027740:nerve' index='T92' start='31'> nerve blockade </entity>
		</sent>
		<sent>
			<text>Each patient in the radiofrequency treatment group ( 15 patients ) received an 80 C radiofrequency lesion of the dorsal ramus of the segmental nerve roots L3 , L4 , and L5 .</text>
			<entity class='Intervention' UMLS='' index='T93' start='4'> radiofrequency </entity>
			 <entity class='Intervention' UMLS='C0221198:lesion' index='T94' start='13'> 80 C radiofrequency lesion </entity>
		</sent>
		<sent>
			<text>Patients in the control group ( n = 16 ) underwent an the same procedure but without use of a radiofrequency current .</text>
			<entity class='Intervention' UMLS='' index='T95' start='3'> control </entity>
			 <entity class='Intervention' UMLS='' index='T96' start='20'> radiofrequency current </entity>
		</sent>
		<sent>
			<text>Both the treating physician and the patients were blinded to the group assignment .</text>
			
		</sent>
		<sent>
			<text>Before treatment , physical impairment , rating of pain , the degree of disability , and quality of life were assessed by a blinded investigator .</text>
			<entity class='Outcome' UMLS='C0231171:physical impairment' index='T97' start='3'> physical impairment </entity>
			 <entity class='Outcome' UMLS='C0030193:pain' index='T98' start='6'> rating of pain </entity>
			 <entity class='Outcome' UMLS='C0231170:disability,C0542560:degree' index='T99' start='11'> degree of disability </entity>
			 <entity class='Outcome' UMLS='C0518214:quality of life' index='T100' start='16'> quality of life </entity>
		</sent>
	</abstract>

	<abstract>
		<sent>
			<text>PMID:10588598</text>
			
		</sent>
		<sent>
			<text>A total of 642 patients with chronic asthma ( FEV ( 1 ) 50 to 85 % of predicted value and at least a predefined level of asthma symptoms ) incompletely controlled with inhaled beclomethasone , 200 microg twice daily using a spacer device , during the4 - wk run - in period were randomly allocated , in a double - blind , double - dummy manner to one of four treatment groups : ( 1 ) montelukast 10 mg plus continuing inhaled beclomethasone ; ( 2 ) placebo tablet plus continuing inhaled beclomethasone ; ( 3 ) montelukast 10 mg and inhaled placebo ( after blind beclomethasone removal ) ; and ( 4 ) placebo tablet and inhaled placebo ( after blind beclomethasone removal ) .</text>
			<entity class='Participant' UMLS='C0877430:chronic asthma' index='T101' start='6'> chronic asthma </entity>
			 <entity class='Participant' UMLS='' index='T102' start='9'> FEV </entity>
			 <entity class='Participant' UMLS='C1457887:symptoms,C0004096:asthma' index='T103' start='27'> asthma symptoms </entity>
			 <entity class='Intervention' UMLS='C2065042:inhaled beclomethasone' index='T104' start='33'> inhaled beclomethasone </entity>
			 <attribute class='measure' index='T105' start='36'> 200 microg twice daily </attribute>
			 <entity class='Intervention' UMLS='C2065042:inhaled beclomethasone,C0298130:montelukast' index='T106' start='77'> montelukast 10 mg plus continuing inhaled beclomethasone </entity>
			 <entity class='Intervention' UMLS='C2065042:inhaled beclomethasone,C0032042:placebo' index='T107' start='88'> placebo tablet plus continuing inhaled beclomethasone </entity>
			 <entity class='Intervention' UMLS='C0298130:montelukast' index='T108' start='98'> montelukast </entity>
			 <attribute class='measure' index='T109' start='99'> 10 mg </attribute>
			 <entity class='Intervention' UMLS='C0004048:inhaled,C0032042:placebo' index='T110' start='102'> inhaled placebo </entity>
			 <entity class='Intervention' UMLS='C0032042:placebo' index='T111' start='115'> placebo tablet </entity>
			 <entity class='Intervention' UMLS='C0004048:inhaled,C0032042:placebo' index='T112' start='118'> inhaled placebo </entity>
		</sent>
		<sent>
			<text>The primary endpoints were FEV ( 1 ) and daytime asthma symptoms score .</text>
			<entity class='Outcome' UMLS='' index='T113' start='4'> FEV ( 1 ) </entity>
			 <entity class='Outcome' UMLS='C1457887:symptoms,C0004096:asthma' index='T114' start='9'> daytime asthma symptoms score </entity>
		</sent>
	</abstract>

	<abstract>
		<sent>
			<text>PMID:10593347</text>
			
		</sent>
		<sent>
			<text>SUBJECTS AND METHODS : After a run - in phase , 318 subjects were randomized to receive one of the following margarine - like spreads containing stanol ester or placebo for 8 weeks : EU 3 G : 1 g of stanol ( ester form ) per 8 - g serving of a European formula 3 times a day ; US 3 G : 1 g of stanol ( ester form ) per 8 - g serving of a US reformulation 3 times a day ; US 2 G : 0.67 g of stanol ( ester form ) per 8 - g serving of a US reformulation 3 times a day ; or placebo spread .</text>
			<entity class='Intervention' UMLS='' index='T115' start='21'> margarine </entity>
			 <entity class='Intervention' UMLS='' index='T116' start='26'> stanol ester </entity>
			 <entity class='Intervention' UMLS='C0032042:placebo' index='T117' start='29'> placebo </entity>
			 <attribute class='measure' index='T118' start='38'> 1 g </attribute>
			 <entity class='Intervention' UMLS='' index='T119' start='41'> stanol </entity>
			 <entity class='Intervention' UMLS='' index='T120' start='53'> European formula </entity>
			 <attribute class='measure' index='T121' start='64'> 1 g </attribute>
			 <entity class='Intervention' UMLS='' index='T122' start='67'> stanol ( ester form ) per 8 - g serving of a US reformulation </entity>
			 <attribute class='measure' index='T123' start='90'> 0.67 g </attribute>
			 <entity class='Intervention' UMLS='' index='T124' start='93'> stanol ( ester form ) per 8 - g serving of a US reformulation </entity>
			 <entity class='Intervention' UMLS='C0032042:placebo' index='T125' start='113'> placebo </entity>
		</sent>
	</abstract>
</root>
